CINECA IRIS Institutional Research Information System

FERRARI, SILVIA MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.098
AS - Asia 7.721
EU - Europa 6.092
SA - Sud America 1.476
AF - Africa 260
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 7
Totale 33.675
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.639
IT - Italia 2.412
SG - Singapore 2.382
CN - Cina 2.082
HK - Hong Kong 1.344
BR - Brasile 1.235
SE - Svezia 837
VN - Vietnam 799
BG - Bulgaria 523
DE - Germania 473
FI - Finlandia 425
CA - Canada 335
FR - Francia 314
GB - Regno Unito 304
RU - Federazione Russa 300
TR - Turchia 287
IN - India 167
UA - Ucraina 114
IQ - Iraq 95
JP - Giappone 93
BD - Bangladesh 91
NL - Olanda 86
AR - Argentina 84
CI - Costa d'Avorio 60
MX - Messico 60
PL - Polonia 53
KR - Corea 48
AT - Austria 41
ID - Indonesia 41
ES - Italia 40
ZA - Sudafrica 40
EC - Ecuador 36
CO - Colombia 33
PK - Pakistan 32
SA - Arabia Saudita 32
MA - Marocco 31
SN - Senegal 30
VE - Venezuela 29
CH - Svizzera 28
BE - Belgio 26
PH - Filippine 25
NG - Nigeria 24
UZ - Uzbekistan 24
PY - Paraguay 22
CZ - Repubblica Ceca 20
AU - Australia 18
IE - Irlanda 18
JO - Giordania 18
TN - Tunisia 16
IR - Iran 15
MY - Malesia 15
NP - Nepal 15
AE - Emirati Arabi Uniti 14
KE - Kenya 14
LT - Lituania 12
RO - Romania 12
TH - Thailandia 12
JM - Giamaica 11
PE - Perù 11
UY - Uruguay 11
DZ - Algeria 10
EG - Egitto 10
OM - Oman 10
AL - Albania 9
DO - Repubblica Dominicana 9
GT - Guatemala 9
IL - Israele 9
KZ - Kazakistan 9
LB - Libano 8
CL - Cile 7
GR - Grecia 7
HN - Honduras 7
TT - Trinidad e Tobago 7
BH - Bahrain 6
BJ - Benin 6
BY - Bielorussia 6
HU - Ungheria 6
PS - Palestinian Territory 6
RS - Serbia 6
GE - Georgia 5
NI - Nicaragua 5
TW - Taiwan 5
AM - Armenia 4
AZ - Azerbaigian 4
BN - Brunei Darussalam 4
BO - Bolivia 4
CR - Costa Rica 4
DK - Danimarca 4
ET - Etiopia 4
EU - Europa 4
GY - Guiana 4
KG - Kirghizistan 4
PA - Panama 4
BB - Barbados 3
HR - Croazia 3
KW - Kuwait 3
MD - Moldavia 3
PT - Portogallo 3
QA - Qatar 3
XK - ???statistics.table.value.countryCode.XK??? 3
Totale 33.635
Salva come PNG Salva come JPEG
Città #
Fairfield 1.867
Ashburn 1.847
Woodbridge 1.525
Singapore 1.346
Hong Kong 1.325
Houston 1.061
Dallas 1.037
San Jose 921
Santa Clara 863
Ann Arbor 840
Seattle 817
Chandler 796
Serra 790
Cambridge 685
Wilmington 664
Shanghai 536
Sofia 522
Milan 488
Beijing 438
New York 356
Boardman 265
Council Bluffs 258
Princeton 257
Pisa 243
Helsinki 241
Ottawa 237
Los Angeles 224
Lawrence 204
Medford 196
Lauterbourg 182
Ho Chi Minh City 169
Nanjing 146
Dong Ket 139
Izmir 134
Des Moines 130
Munich 118
Jacksonville 114
São Paulo 110
Hanoi 101
Istanbul 99
London 99
Redondo Beach 96
Florence 92
Buffalo 90
Frankfurt am Main 89
San Diego 87
Tokyo 82
Columbus 81
Rome 78
Hefei 77
The Dalles 77
Dearborn 73
Abidjan 60
Boulder 52
Seoul 47
Paris 45
Nanchang 40
Rio de Janeiro 40
Redwood City 39
Kunming 37
Ogden 37
Warsaw 37
Da Nang 36
Chicago 35
Falls Church 35
Fuzhou 35
Phoenix 35
Turku 35
Baghdad 33
Bremen 33
Shenyang 33
Hebei 32
Changsha 31
Dakar 30
Norwalk 29
Nuremberg 29
Belo Horizonte 26
Brooklyn 25
Brussels 25
Dhaka 25
San Francisco 25
Jiaxing 24
Pune 24
Toronto 24
Amsterdam 23
Johannesburg 23
Rho 23
Orem 22
Sulaymaniyah 22
Tashkent 22
Tianjin 22
Vienna 22
Washington 22
Chennai 21
Denver 21
Guangzhou 21
Haiphong 21
Montreal 21
Lagos 20
Brasília 19
Totale 24.750
Salva come PNG Salva come JPEG
Nome #
Autoimmune thyroid disorders 300
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 254
Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes: Response to Skowronski et al. 247
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 247
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy 243
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 236
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 229
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. 228
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 227
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 227
Molecular testing in the diagnosis of differentiated thyroid carcinomas 225
Sorafenib in the treatment of thyroid cancer 225
Aggressive thyroid cancer: targeted therapy with sorafenib 223
Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia 217
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors 215
Sunitinib in the treatment of thyroid cancer 214
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
Sorafenib and Thyroid Cancer 209
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts 206
Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature 204
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases 203
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study 200
TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation 197
The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients 195
Selective use of vandetanib in the treatment of thyroid cancer 194
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 193
Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10 191
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 189
Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection 188
CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer 188
Cabozantinib in Thyroid Cancer 188
Novel therapies for thyroid autoimmune diseases: An update 188
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy 188
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 187
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone 187
New insight in endocrine-related adverse events associated to immune checkpoint blockade 187
Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied 186
Thyroid disorders induced by checkpoint inhibitors 185
Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ 183
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide 182
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors 182
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic Review 181
CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes 181
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition 181
Cytokines and HCV-Related Disorders. 179
Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine 177
Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study 177
Cytokines and HCV-related autoimmune disorders 176
Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy 176
RET TKI: Potential Role in Thyroid Cancers 175
Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. 174
Novel treatments for anaplastic thyroid carcinoma 172
High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C 170
New targeted molecular therapies for dedifferentiated thyroid cancer. 169
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses 169
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells 166
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests 166
3,5-diiodo-l-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. 165
New targeted therapies for anaplastic thyroid cancer. 165
Myo-inositol in autoimmune thyroiditis, and hypothyroidism 163
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series 163
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy 163
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy 162
Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy 161
Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells 161
Endocrine Manifestations of HCV-Positive Cryoglobulinemia 161
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? 161
Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up 161
The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine 161
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update 160
Thyroid involvement in hepatitis C - Associated mixed cryoglobulinemia 160
Chemokines in thyroid autoimmunity 158
Thyroid uptake of 67Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis. 158
High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ. 158
Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up 158
Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. 157
Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis 156
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration 156
Immune and inflammatory cells in thyroid cancer microenvironment 156
The emerging extrahepatic manifestations oh hepatitis C virus infection in chronic hepatitis and mixed cryoglobulinemia. 155
Novel treatment options for anaplastic thyroid cancer 155
Nutraceuticals in thyroidology: A review of in vitro, and in vivo animal studies 155
Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. 154
Thyroid Autoimmunity and SARS-CoV-2 Infection 153
Current and future immunotherapies for thyroid cancer 153
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer 153
Tyrosine Kinase Inhibitors; Therapies for Thyroid Cancer 152
Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. 150
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. 150
Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. 150
Hepatitis C virus infection - Evidence for an association with type 2 diabetes 150
High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. 149
Novel Therapies for Thyroid Autoimmune Diseases 149
CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide 149
Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study 149
Both 3,5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion 149
Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis 148
The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results 148
Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. 147
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer 147
Totale 18.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.422
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.422
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021364 0 0 0 0 0 0 0 0 0 0 0 364
2021/20222.495 42 116 112 158 412 329 75 163 133 86 166 703
2022/20232.421 361 293 160 194 271 340 46 166 353 11 189 37
2023/20242.112 183 233 257 183 315 385 118 73 35 43 69 218
2024/20257.032 158 267 112 444 702 911 574 395 604 868 724 1.273
2025/20268.674 656 1.001 1.160 734 728 797 1.354 417 501 880 258 188
Totale 34.571